Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice: results from the COMPLY observational study

The problem of medication adherence is still relevant, and the search for a reliable method for its diagnosis continues. One of the most convenient and promising ways to assess medication adherence, both in research and actual clinical practice, is the use of various questionnaires and scores. Currently, several dozen different questionnaires and scores are presented in Russia and other countries. All of them are indirect methods of adherence assessment and are characterized by subjectivity. The article presents data on the most famous and widely used foreign adherence scales (the 4- and 8-item Morisky Medication Adherence Scale (MMAS-4 and MMAS-8), Hill-Bone, SEAMS, BMQ, MARS, etc.) and several questionnaires proposed by Russian authors (the National Society of Evidence-based Pharmacotherapy Adherence Scale, the Quantitative Adherence Questionnaire and the National Questionnaire of Treatment Compliance). The main characteristics of the described scales, their advantages, disadvantages and prospects for use in studies and clinical practice are considered. There are following conclusions: 1) none of the current questionnaires is devoid of subjectivity; 2) almost all questionnaires overestimate medication adherence, do not fully diagnose nonadherence, and often determine only specific type of adherence; 3) even validated questionnaires, which used in patients with different diseases in various countries, can have different values of sensitivity, specificity and reliability — from excellent to very poor; 4) in this regard, the results should be skeptically and cautiously interpreted; 5) in actual clinical practice, preference should be given to concise scales that include no more than 10 questions, with a simple scoring system, preferably validated with using well-known criteria from large clinical trials; 6) to improve the diagnosis accuracy, usage of several available methods for assessing medication adherence is recommended.

Download Full-text

A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study

Journal of Ophthalmology ◽

10.1155/2014/857148 ◽

2014 ◽

Vol 2014 ◽

pp. 1-9 ◽

Cited By ~ 15

Author(s):

Sergio Pagliarini ◽

Stephen Beatty ◽

Blandina Lipkova ◽

Eduardo Perez-Salvador Garcia ◽

Stefaan Reynders ◽

...

Keyword(s):

Clinical Practice ◽

Observational Study ◽

Macular Degeneration ◽

Safety Profile ◽

Treatment Compliance ◽

Routine Clinical Practice ◽

Age Related Macular Degeneration ◽

Age Related ◽

The Eu ◽

Bilateral Treatment

Purpose. To assess the safety profile of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (nAMD) in routine clinical practice.Methods. This 2-year, multicentre, observational study was conducted to capture real-world early practice and outcomes across Europe, shortly after European licensing of ranibizumab for nAMD. Being observational in nature, the study did not impose diagnostic/therapeutic interventions/visit schedule. Patients were to be treated as per the EU summary of product characteristics (SmPC) in effect during the study. Key outcome measures were incidence of selected adverse events (AEs), treatment exposure, bilateral treatment, compliance to the EU SmPC, and best-corrected visual acuity (BCVA) over 2 years.Results. 755 of 770 patients received treatment. Ranibizumab was generally well tolerated with low incidence of selected AEs (0%–1.9%). Patients received 6.2 (mean) injections and 133 patients received bilateral treatment over 2 years. Protocol deviation to treatment compliance was reported in majority of patients. The observed decline in mean BCVA (Month 12, +1.5; Month 24, –1.3 letters) may be associated with undertreatment as suggested by BCVA subgroup analysis.Conclusion. The EPICOHORT study conducted in routine clinical practice reinforces the well-established safety profile of ranibizumab in nAMD. In early European practice it appeared that the nAMD patients were undertreated.

Download Full-text

Faculty Opinions recommendation of The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.10199.467691 ◽

2006 ◽

Author(s):

Michael Ward

Keyword(s):

Primary Care ◽

Health Care ◽

Clinical Practice ◽

Observational Study ◽

Resource Use ◽

Health Care Resource ◽

Primary Care Patients ◽

Health Care Resource Use ◽

The Uk ◽

The Impact

Download Full-text

Normative values of incremental shuttle walk test in children and adolescents: an observational study

International Journal of Pharma and Bio Sciences ◽

10.22376/ijpbs.2017.8.4.b478-483 ◽

2017 ◽

Vol 8 (4) ◽

Cited By ~ 2

Author(s):

VISHNU VARDHAN ◽

TUSHAR PALEKAR ◽

PRIYANKA DHUKE ◽

GAURANG BAXI

Keyword(s):

Observational Study ◽

Children And Adolescents ◽

Normative Values ◽

Walk Test

Download Full-text

Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring

Scientific Reports ◽

10.1038/s41598-021-91983-w ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Andrea Piolatto ◽

Paola Berchialla ◽

Sarah Allegra ◽

Silvia De Francia ◽

Giovanni Battista Ferrero ◽

...

Keyword(s):

Clinical Practice ◽

Renal Impairment ◽

Observational Study ◽

Iron Overload ◽

Iron Loading ◽

Comprehensive Comparison ◽

Dispersible Tablets ◽

One Year ◽

Safety Features

AbstractDeferasirox (DFX) is the newest among three different chelators available to treat iron overload in iron-loading anaemias, firstly released as Dispersible Tablets (DT) and more recently replaced by Film-Coated Tablets (FCT). In this retrospective observational study, pharmacokinetics, pharmacodynamics, and safety features of DFX treatment were analyzed in 74 patients that took both formulations subsequently under clinical practice conditions. Bioavailability of DFX FCT compared to DT resulted higher than expected [Cmax: 99.5 (FCT) and 69.7 (DT) μMol/L; AUC: 1278 (FCT) and 846 (DT), P < 0.0001]. DFX FCT was also superior in scalability among doses. After one year of treatment for each formulation, no differences were observed between the treatments in the overall iron overload levels; however, DFX FCT but not DT showed a significant dose–response correlation [Spearman r (dose-serum ferritin variation): − 0.54, P < 0.0001]. Despite being administered at different dosages, the long-term safety profile was not different between formulations: a significant increase in renal impairment risk was observed for both treatments and it was reversible under strict monitoring (P < 0.002). Altogether, these data constitute a comprehensive comparison of DFX formulations in thalassaemia and other iron-loading anaemias, confirming the effectiveness and safety characteristics of DFX and its applicability for treatment tailoring.

Download Full-text

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice

Journal of Personalized Medicine ◽

10.3390/jpm11040254 ◽

2021 ◽

Vol 11 (4) ◽

pp. 254

Author(s):

Mezin Öthman ◽

Erik Widman ◽

Ingela Nygren ◽

Dag Nyholm

Keyword(s):

Cardiac Arrest ◽

Clinical Practice ◽

Observational Study ◽

Prospective Studies ◽

Infusion Rate ◽

Treatment Duration ◽

Initial Experience ◽

Morning Dose ◽

Efficacy And Safety ◽

User Friendliness

Patients in fluctuating stages of Parkinson’s disease (PD) require device-aided treatments. Continuous infusion of levodopa–carbidopa intestinal gel (LCIG) is a well-proven option in clinical practice. We now report the first clinical experience of levodopa–entacapone–carbidopa intestinal gel (LECIG) therapy. An observational study of the first patients to start LECIG in our clinic was performed. Twenty-four patients (11 females, 13 males) were included. The median age was 71.5 years, and the median duration since PD diagnosis was 15.5 years. The median treatment duration was 305 days. Median doses were: 6.0 mL as morning dose, 2.5 mL/h as infusion rate, and 1.0 mL as extra dose. Half of the patients were switched directly from LCIG. These patients express improvements in the size and weight of the pump. Furthermore, most of them considered the new pump to be improved regarding user-friendliness. Six patients discontinued LECIG, three due to diarrhea, one due to hallucinations and two deceased (one cardiac arrest and one COVID-19). LECIG has shown to be possible to use in patients with PD, efficacy and safety as expected. Patients are generally happy with the size and usability of the pump, but some technical improvements of the software are warranted, as well as larger, prospective studies.

Download Full-text

Physiological and pathological roles of the accommodation response in lower esophageal sphincter relaxation during wet swallows

Scientific Reports ◽

10.1038/s41598-021-87052-x ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Kazumasa Muta ◽

Eikichi Ihara ◽

Shohei Hamada ◽

Hiroko Ikeda ◽

Masafumi Wada ◽

...

Keyword(s):

Clinical Practice ◽

High Resolution ◽

Observational Study ◽

Lower Esophageal Sphincter ◽

Relaxation Function ◽

Esophagogastric Junction ◽

Prospective Observational Study ◽

Outflow Obstruction ◽

High Resolution Manometry ◽

Esophageal Sphincter

AbstractThe preparatory accommodation response of lower esophageal sphincter (LES) before swallowing is one of the mechanisms involved in LES relaxation during wet swallows, however, the physiological and/or pathological roles of LES accommodation remain to be determined in humans. To address this problem, we conducted a prospective observational study of 38 patients with normal high-resolution manometry (HRM) and 23 patients with idiopathic esophagogastric junction outflow obstruction (EGJOO) to assess dry and wet swallows. The LES accommodation measurement was proposed for practical use in evaluating the LES accommodation response. Although swallow-induced LES relaxation was observed in both dry and wet swallows, LES accommodation (6.4, 3.1–11.1 mmHg) was only observed in wet swallows. The extent of LES accommodation was impaired in idiopathic EGJOO (0.6, − 0.6–6 mmHg), and the LES accommodation measurement of patients with idiopathic EGJOO (36.8, 29.5–44.3 mmHg) was significantly higher in comparison to those with normal HRM (23.8, 18–28.6 mmHg). Successful LES relaxation in wet swallowing can be achieved by LES accommodation in combination with swallow-induced LES relaxation. Impaired LES accommodation is characteristic of idiopathic EGJOO. In addition to the IRP value, the LES accommodation measurement may be useful for evaluating the LES relaxation function in clinical practice.

Download Full-text